Xin An

3.3k total citations
102 papers, 2.1k citations indexed

About

Xin An is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Xin An has authored 102 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Oncology, 35 papers in Pulmonary and Respiratory Medicine and 25 papers in Surgery. Recurrent topics in Xin An's work include HER2/EGFR in Cancer Research (11 papers), Breast Cancer Treatment Studies (9 papers) and Bladder and Urothelial Cancer Treatments (9 papers). Xin An is often cited by papers focused on HER2/EGFR in Cancer Research (11 papers), Breast Cancer Treatment Studies (9 papers) and Bladder and Urothelial Cancer Treatments (9 papers). Xin An collaborates with scholars based in China, United States and Belgium. Xin An's co-authors include Amit K. Tiwari, Pei-Rong Ding, Zhe‐Sheng Chen, Hua Zhu, Tao Tan, Yibo Sun, Charles R. Ashby, Yuan Cao, Jihua Chen and Lina Yang and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and JNCI Journal of the National Cancer Institute.

In The Last Decade

Xin An

90 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xin An China 24 823 689 452 398 244 102 2.1k
Ming Jin China 20 643 0.8× 452 0.7× 351 0.8× 225 0.6× 234 1.0× 79 1.5k
Ala Abudayyeh United States 22 553 0.7× 750 1.1× 197 0.4× 286 0.7× 201 0.8× 80 1.7k
Stephan Macher‐Goeppinger Germany 28 1.1k 1.4× 436 0.6× 448 1.0× 527 1.3× 358 1.5× 59 2.1k
Jinglin Xia China 30 1.2k 1.5× 694 1.0× 702 1.6× 463 1.2× 375 1.5× 107 2.8k
Kathy Gately Ireland 24 808 1.0× 519 0.8× 366 0.8× 515 1.3× 120 0.5× 79 1.8k
Sérgio Rizzo Italy 25 559 0.7× 1.0k 1.5× 402 0.9× 635 1.6× 124 0.5× 74 2.0k
Dapeng Wu China 24 903 1.1× 481 0.7× 421 0.9× 307 0.8× 133 0.5× 88 1.8k
Dimitrios Spentzos United States 26 1.7k 2.0× 567 0.8× 913 2.0× 443 1.1× 94 0.4× 43 2.6k
Huiqin Chen United States 21 1.1k 1.3× 1.0k 1.5× 726 1.6× 543 1.4× 118 0.5× 62 2.2k
Chiara Paglino Italy 19 1.3k 1.6× 769 1.1× 618 1.4× 800 2.0× 159 0.7× 46 2.4k

Countries citing papers authored by Xin An

Since Specialization
Citations

This map shows the geographic impact of Xin An's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xin An with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xin An more than expected).

Fields of papers citing papers by Xin An

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xin An. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xin An. The network helps show where Xin An may publish in the future.

Co-authorship network of co-authors of Xin An

This figure shows the co-authorship network connecting the top 25 collaborators of Xin An. A scholar is included among the top collaborators of Xin An based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xin An. Xin An is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
An, Xin, et al.. (2025). Transition and trajectory of spatiotemporal characterization of waste photovoltaics in China: 2013–2060. Renewable Energy. 249. 123214–123214. 1 indexed citations
2.
Dun, S.L., Qifeng Zhou, Wen Xia, et al.. (2025). Real-world outcomes of trastuzumab deruxtecan in HR-negative HER2-low metastatic breast cancer. npj Breast Cancer. 11(1). 123–123.
3.
Sun, Qi, et al.. (2024). Primary adenocarcinoma of the spermatic cord: a case report and review of the literature. Diagnostic Pathology. 19(1). 136–136.
4.
Lu, Yongkui, Lixia Li, Meiting Chen, et al.. (2024). Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study. BMC Cancer. 24(1). 1214–1214.
5.
Chen, Meiting, et al.. (2024). Optimal Sequential Strategies for Antibody-Drug Conjugate in Metastatic Breast Cancer: Evaluating Efficacy and Cross-Resistance. The Oncologist. 29(8). e957–e966. 22 indexed citations
6.
Liang, Jianwen, Chunyan Li, Qingguang Lin, et al.. (2024). Development and validation of ultrasound-based radiomics model to predict germline BRCA mutations in patients with breast cancer. Cancer Imaging. 24(1). 31–31. 7 indexed citations
7.
8.
Ni, Ming, Lanlan Zhou, You Lü, et al.. (2023). 63P Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer. Annals of Oncology. 34. S1490–S1490.
9.
Hong, Ruoxi, Wen Xia, Liye Wang, et al.. (2021). Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2‐positive breast cancer: An open‐label, dose‐escalation, phase I study. Cancer Communications. 41(2). 171–182. 23 indexed citations
10.
Yang, Anli, Ying Zhou, Yanan Kong, et al.. (2021). Identification and Validation of Immune-Related Methylation Clusters for Predicting Immune Activity and Prognosis in Breast Cancer. Frontiers in Immunology. 12. 704557–704557. 2 indexed citations
11.
An, Xin, Xi Lin, Anli Yang, et al.. (2020). Cavin3 Suppresses Breast Cancer Metastasis via Inhibiting AKT Pathway. Frontiers in Pharmacology. 11. 1228–1228. 3 indexed citations
12.
Bachelot, Thomas, NU Lin, Sara A. Hurvitz, et al.. (2020). 293P Impact of tucatinib on progression free survival in patients with HER2+ metastatic breast cancer and stable or active brain metastases. Annals of Oncology. 31. S359–S360. 9 indexed citations
13.
Niu, Jinzhi, Wanjun Yang, Yuan Tian, et al.. (2019). Topical dsRNA delivery induces gene silencing and mortality in the pea aphid. Pest Management Science. 75(11). 2873–2881. 62 indexed citations
14.
Xue, Cong, Wenwen Wei, Peng Sun, et al.. (2018). Pretreatment anti-Mullerian hormone-based nomogram predicts menstruation status after chemotherapy for premenopausal women with hormone receptor-positive early breast cancer. Breast Cancer Research and Treatment. 173(3). 619–628. 10 indexed citations
15.
16.
Zhang, Le, Jing Zeng, Feng‐Hua Wang, et al.. (2016). MGMT in colorectal cancer: a promising component of personalized treatment. Tumor Biology. 37(8). 11443–11456. 10 indexed citations
17.
Zhang, Le, Yan Deng, Feng Hua Wang, et al.. (2012). Efficacy of the FOLFOX/CAPOX regimen for advanced small bowel adenocarcinoma: a three-center study from China.. PubMed. 16(4). 689–96. 20 indexed citations
18.
19.
Li, Yuhong, Fang Wang, Lin Shen, et al.. (2010). EGFR Fluorescence In situ Hybridization Pattern of Chromosome 7 Disomy Predicts Resistance to Cetuximab in KRAS Wild-type Metastatic Colorectal Cancer Patients. Clinical Cancer Research. 17(2). 382–390. 24 indexed citations
20.
An, Xin, Amit K. Tiwari, Yibo Sun, et al.. (2010). BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review. Leukemia Research. 34(10). 1255–1268. 232 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ming Jin Breakdown of academic impact, for papers by Ala Abudayyeh Breakdown of academic impact, for papers by Stephan Macher‐Goeppinger Breakdown of academic impact, for papers by Jinglin Xia Breakdown of academic impact, for papers by Kathy Gately Breakdown of academic impact, for papers by Sérgio Rizzo Breakdown of academic impact, for papers by Dapeng Wu Breakdown of academic impact, for papers by Dimitrios Spentzos Breakdown of academic impact, for papers by Huiqin Chen Breakdown of academic impact, for papers by Chiara Paglino
Rankless by CCL
2026